Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

GSK’s DoJ Settlement Requires Execs To Forfeit Bonuses If Misconduct Occurs

Jul 02 2012

• By Brenda Sandburg

Related Content

GSK’s $750 Mil. DoJ Settlement: When GMP Violations Equal Healthcare Fraud

Nov 01 2010

GSK’s Deal With DoJ Is Fourth In Eight Years; Exec Liability Uncertain

Nov 07 2011

Dismissal Of Indictment Against Former GSK Attorney May Bode Well For Pharma

Mar 24 2011

Pfizer's Record-Breaking $2.3 Bil. Settlement With U.S. Attorney Imposes New Restrictions on Corporate Behavior

Sep 07 2009

The Era Of Billion Dollar Pharma Settlements

Jun 11 2012

Related Companies

GSK plc

Pfizer Inc.

Abbott

Eli Lilly and Company

Johnson & Johnson

Omnicare Inc.

Additional Topics

Legal Issues BioPharmaceutical

More from Legal & IP

More from Pink Sheet

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window